Revolution Medicines, Inc. (RVMD) News
Follow Revolution Medicines, Inc. (RVMD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 67 public stories across 33 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A Revolution Medicines, Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:25 PM UTC
M
Revolution Medicines Reports Q3 Revenue of $197.6M
EQUITY | Nov 04, 2026, 09:06 PM UTC
M
Revolution Medicines Receives FDA Approval and Launches RASONQUE
Revolution Medicines received U.S. FDA approval and launched RASONQUE (daraxonrasib) for adults with metastatic disease. The provided text does not specify the disease.
EQUITY | Nov 04, 2026, 09:05 PM UTC
M
Revolution Medicines Reports $407.5M Third-Quarter Loss
EQUITY | Nov 04, 2026, 09:04 PM UTC
M
Revolution Medicines Reports Third-Quarter Loss of $1.90 per Share
EQUITY | Nov 04, 2026, 09:02 PM UTC
M
Revolution Medicines Q3 Results Due November 4 After Close
Revolution Medicines is scheduled to report Q3'26 results after the market closes on November 4.
EQUITY | Nov 03, 2026, 12:01 PM UTC
M
Revolution Medicines Q3'26 Earnings Preview
Revolution Medicines is scheduled to report Q3'26 results on November 04 after the market closes, with EPS anticipated at (2.35) USD.
EQUITY | Oct 28, 2026, 11:00 AM UTC
M
Revolution Medicines Reports Daraxonrasib Survival Benefit Across PDAC Subgroups
Exploratory Phase 3 RASolute 302 subgroup data showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (HR 0.40) in previously treated metastatic PDAC, consistent with the prim
EQUITY | Oct 23, 2026, 11:35 AM UTC
M
EU Regulators Give Positive Opinion to Revolution Medicines Pancreatic Cancer Treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Rasonque, also known generically as daraxonrasib, for adults.
REGULATION | Oct 15, 2026, 03:58 PM UTC
L
EU CHMP Recommends Marketing Authorisation for Rasonque
The EMA’s Committee for Medicinal Products for Human Use recommended granting marketing authorisation for Rasonque for metastatic pancreatic cancer in the EU.
REGULATION | Oct 15, 2026, 02:36 PM UTC
M
EMA Panel Recommends EU Approval of Revolution Medicines’ Pancreatic Cancer Drug
The European Medicines Agency committee recommended approval of Rasonque for adults with pancreatic cancer that has spread and worsened after at least one prior treatment.
REGULATION | Oct 15, 2026, 02:01 PM UTC
M
EMA Recommends EU Approval of Revolution Medicines’ Pancreatic Cancer Drug
The European Medicines Agency recommended approval of Revolution Medicines’ Rasonque in the EU.
REGULATION | Oct 15, 2026, 01:48 PM UTC
L
Revolution Medicines’ daraxonrasib wins positive EU CHMP opinion
The CHMP recommended marketing authorization in the European Union for metastatic pancreatic cancer.
REGULATION | Oct 15, 2026, 01:45 PM UTC
H
Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%
U.S. stocks slipped by midday Thursday as oil surged more than 5% on fresh Persian Gulf tanker attacks, while Treasury yields climbed back toward their highest levels since 2002 and the Federal Reserve’s hawkish minutes
LIVE | Oct 08, 2026, 05:25 PM UTC
M
Revolution Medicines Starts Phase 3 Trial for Pancreatic Cancer Drug
Revolution Medicines has begun treating patients in its Phase 3 RASolute 309 trial for its drug daraxonrasib (RASONQUE™) combined with zoldonrasib. The trial is evaluating the combination as a first-line treatment for me
EQUITY | Oct 05, 2026, 12:09 PM UTC
L
Revolution Medicines Price Target Announced at $318.00/Share by Brookline Capital
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 05:05 PM UTC
L
Revolution Medicines Price Target Announced at $267.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:31 PM UTC
L
RVMD - zoldonrasib Receives orphan drug designation
RVMD - zoldonrasib Receives orphan drug designation
NEWS | Sep 15, 2026, 06:52 PM UTC
L
Revolution Medicines Gets FDA Breakthrough Designation for Cancer Treatment
By Katherine HamiltonRevolution Medicines received breakthrough therapy designation from the Food and Drug Administration for its treatment of pancreatic cancer.The designation is for Rasonque to treat metastatic pancrea
REGULATION | Sep 14, 2026, 08:46 PM UTC
L
RVMD - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
RVMD - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
REGULATION | Sep 14, 2026, 08:05 PM UTC
M
Revolution Medicines gets approval for daraxonrasib in metastatic pancreatic cancer
Regulators approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma, according to the report. Revolution Medicines is described as having received the landmark approval of its pancreatic cancer pill l
REGULATION | Sep 10, 2026, 06:40 PM UTC
L
Revolution Medicines initiated at Morgan Stanley with overweight rating
Morgan Stanley initiated Revolution Medicines (NASDAQ: RVMD) with an overweight rating. The firm set a $255 price target, citing the company’s pipeline of RAS(“ON”) inhibitors.
EQUITY | Sep 10, 2026, 03:51 PM UTC
L
Revolution Medicines price target set at $255 by Morgan Stanley
Morgan Stanley initiated a $255.00 per-share price target for Revolution Medicines. Benzinga also reported the firm initiated the stock at Overweight.
EQUITY | Sep 10, 2026, 12:19 PM UTC
L
Stifel raises Revolution Medicines price target to $230 from $215
Stifel maintained Revolution Medicines at Buy and raised its price target to $230.00 per share from $215.00, according to Benzinga/TradingView News.
EQUITY | Sep 09, 2026, 03:12 PM UTC
M
Revolution Medicines shares jump after FDA approval for Rasonque
Revolution Medicines (RVMD) surged after FDA approval of Rasonque. Trials showed ~60% lower death risk versus chemo, with median OS 13.2 vs 6.7 months and PFS 7.2 vs 3.6. Shares consolidated around $210.
REGULATION | Sep 07, 2026, 11:22 AM UTC
L
NEJM publishes Revolution Medicines Phase 1/2 data on RASONQUE™ in NSCLC
Revolution Medicines said The New England Journal of Medicine has published Phase 1/2 clinical data for RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer.
EQUITY | Sep 02, 2026, 09:57 PM UTC
L
NEJM publishes RVMD Phase 1/2 data on RASONQUE in metastatic NSCLC
NEJM published Phase 1/2 clinical data on Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer.
EQUITY | Sep 02, 2026, 09:50 PM UTC
L
Sanders blasts high cancer drug prices after RVMD approval
Sen. Bernie Sanders said the cost of new cancer drugs is driving financial ruin for patients, citing a 42% life-savings depletion figure without naming the source. The post followed Revolution Medicines' late-August FDA
REGULATION | Sep 02, 2026, 10:56 AM UTC
L
RVMD launches RASONQUE at $39,800; Guggenheim PT $275
RVMD launches RASONQUE priced at $39,800. Guggenheim raises its price target to $275.
EQUITY | Aug 29, 2026, 07:14 AM UTC
L
UBS raises Revolution Medicines price target to $265
UBS raised its Revolution Medicines price target to $265.00 per share from $220.00.
EQUITY | Aug 28, 2026, 04:47 PM UTC
L
Revolution Medicines maintained as Buy by Guggenheim
Revolution Medicines (RVMD) remains rated Buy by Guggenheim, per TradingView News.
EQUITY | Aug 28, 2026, 01:04 PM UTC
L
Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent — WSJ
Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent — WSJ
EQUITY | Aug 28, 2026, 01:22 AM UTC
L
Revolution Medicine CEO says insurers should act swiftly on $39,800 drug
Revolution Medicine’s CEO Goldsmith expects insurers to provide coverage swiftly for its $39,800 monthly cancer drug.
EQUITY | Aug 27, 2026, 06:54 PM UTC
L
RBC Capital maintains Outperform on Revolution Medicines
RBC Capital maintained an Outperform rating on Revolution Medicines.
EQUITY | Aug 27, 2026, 02:40 PM UTC
L
Revolution Medicines maintained at Outperform by Wedbush
Wedbush maintained its Outperform rating on Revolution Medicines.
EQUITY | Aug 27, 2026, 01:34 PM UTC
L
Truist Securities raises Revolution Medicines target to $239
Truist Securities raised its price target for Revolution Medicines to $239.00 per share from $231.00.
EQUITY | Aug 27, 2026, 01:12 PM UTC
L
Evercore ISI Maintains Outperform on Revolution Medicines
Evercore ISI Group maintained an Outperform rating on Revolution Medicines.
EQUITY | Aug 27, 2026, 12:54 PM UTC
M
Veeva, Revolution Medicines, Pulse Biosciences flagged as overbought
Veeva Systems reported better-than-expected second-quarter results and raised FY27 guidance above estimates, while Revolution Medicines said the FDA approved Rasonque for metastatic pancreatic adenocarcinoma. Pulse Biosc
REGULATION | Aug 27, 2026, 12:46 PM UTC
L
HC Wainwright raises Revolution Medicines PT to $280
HC Wainwright & Co. raised its price target on Revolution Medicines to $280.00 from $195.00.
EQUITY | Aug 27, 2026, 12:26 PM UTC
L
RVMD drug approval chatter; SLS leukemia pipeline focus
TradingView News says market attention is on RVMD’s drug approval, while near-term focus remains on SLS’s leukemia pipeline.
EQUITY | Aug 26, 2026, 10:22 PM UTC
H
RVMD FDA approves RASONQUE for metastatic pancreatic cancer
RVMD says the FDA approved RASONQUE and plans an immediate U.S. launch for metastatic pancreatic cancer.
REGULATION | Aug 26, 2026, 09:37 PM UTC
M
RVMD FDA approves RASONQUE for metastatic pancreatic cancer
RVMD says the FDA approved RASONQUE, a targeted RAS inhibitor for metastatic pancreatic cancer, and it is now available in the U.S.
REGULATION | Aug 26, 2026, 08:41 PM UTC
L
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. — Barrons.com
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. — Barrons.com
REGULATION | Aug 26, 2026, 08:27 PM UTC
L
RVMD stock stays flat after FDA nod for $39,800/month pill
RVMD shares were reported flat despite an FDA nod for a pancreatic cancer pill priced at $39,800 per month.
REGULATION | Aug 26, 2026, 07:52 PM UTC
L
Nvidia, Meta, Revolution Medicines, Abercrombie, Intuit, Salesforce, Moderna, and More Stocks That Explain Today's Market — Barrons.com
Nvidia, Meta, Revolution Medicines, Abercrombie, Intuit, Salesforce, Moderna, and More Stocks That Explain Today's Market — Barrons.com
EQUITY | Aug 26, 2026, 06:52 PM UTC
M
RVMD FDA approval for RASONQUE in metastatic pancreatic cancer
RVMD received FDA approval for RASONQUE, a first-in-class RAS inhibitor, for metastatic pancreatic cancer following Phase 3 results.
REGULATION | Aug 26, 2026, 06:48 PM UTC
M
FDA approves Revolution Medicines RASONQUE
TradingView News says Revolution Medicines has reported U.S. FDA approval for its RASONQUE.
REGULATION | Aug 26, 2026, 06:04 PM UTC
M
FDA approves RVMD’s RASONQUE for metastatic pancreatic cancer
The U.S. FDA has approved Revolution Medicines’ RASONQUE™ (daraxonrasib) for metastatic pancreatic cancer, according to TradeXchange Newsdesk.
REGULATION | Aug 26, 2026, 05:07 PM UTC
L
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. — Barrons.com
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. — Barrons.com
REGULATION | Aug 26, 2026, 03:38 PM UTC
M
FDA approval for targeted therapy in metastatic pancreatic cancer
FDA has approved a first-in-class targeted therapy for metastatic pancreatic cancer, per TradingView News.
REGULATION | Aug 26, 2026, 03:34 PM UTC
L
FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease — WSJ
FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease — WSJ
REGULATION | Aug 26, 2026, 03:18 PM UTC
M
US FDA approves Revolution Medicines pancreatic cancer drug
The US FDA has approved Revolution Medicines' pancreatic cancer drug, according to TradingView News.
REGULATION | Aug 26, 2026, 02:56 PM UTC
L
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ: RVMD ) with a Buy and raises the price target from $210 to $231.
EQUITY | Aug 11, 2026, 05:33 PM UTC
L
RVMD Sees Darax Approval Soon
RVMD expects darax approval soon
EARNINGS | Aug 06, 2026, 10:45 AM UTC
L
RVMD - Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
RVMD - Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
EARNINGS | Aug 05, 2026, 08:02 PM UTC
L
RVMD - Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
RVMD - Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
EARNINGS | Jul 29, 2026, 08:05 PM UTC
L
RVMD - Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancrea
RVMD - Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer Link To Story from REVMED.com
REGULATION | Jul 22, 2026, 09:30 PM UTC
L
Revolution Medicines receives FDA review acceptance for daraxonrasib
Revolution Medicines...
EQUITY | Jul 22, 2026, 09:03 PM UTC
L
EMA accelerates assessment of Revolution Medicines daraxonrasib
Revolution Medicines announced that European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has started a phased review of data on daraxonrasib, the company's investigational RAS multi-select
EQUITY | Jul 07, 2026, 01:27 PM UTC
L
UBS Adjusts Price Target on Revolution Medicines to $220 From $175, Maintains Buy Rating
() -- Revolution Medicines (RVMD) has an average rating of buy and mean price target of $196.86, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research fir
EQUITY | Jul 06, 2026, 02:11 PM UTC